Cell-targeted PD-1 agonists are potent NK-cell inhibitors

BackgroundThe programmed cell death protein 1 (PDCD1 or PD-1) is a key regulatory immune checkpoint and a major target for therapeutic intervention. In oncology, antibodies blocking the PD-1 pathway are used to activate immune cells to promote anti tumour immunity while in immune-mediated inflammato...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Harriet C. Pope, Ana L. Chiodetti, Alice Newey, Guillaume Rieunier, David X. Overton, Eduardo Mateos-Diaz, Tara M. Mahon, Giovanna Bossi, Hussein Al-Mossawi, Charlotte Viant
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-08-01
סדרה:	Frontiers in Immunology
נושאים:	cell-targeted PD-1 agonists NK cell type 1 diabetes autoimmune diseases NK cell inhibition PD-1 pathway
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1640509/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!